LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations

G H Daniels, L Hegedüs, S P Marso, M A Nauck, B Zinman, R M Bergenstal, J F E Mann, J Derving Karsbøl, A C Moses, J B Buse, R M Tuttle, LEADER Trial Investigators, G H Daniels, L Hegedüs, S P Marso, M A Nauck, B Zinman, R M Bergenstal, J F E Mann, J Derving Karsbøl, A C Moses, J B Buse, R M Tuttle, LEADER Trial Investigators

Abstract

Aims: To report preliminary data on baseline serum calcitonin concentrations and associated clinical characteristics in a global population with type 2 diabetes before liraglutide or placebo randomization.

Methods: The ongoing LEADER trial has enrolled 9340 people with type 2 diabetes and at high risk of cardiovascular disease at 410 centres worldwide. People with baseline serum calcitonin ≤ 50 ng/l were randomized to liraglutide once daily or placebo and will be followed for up to 5 years. Serum calcitonin was measured at baseline and will be measured annually thereafter. An independent committee of thyroid experts will oversee calcitonin monitoring throughout the trial and will review all calcitonin concentrations ≥ 20 ng/l.

Results: The mean age of participants was 64.3 ± 7.2 years, 64.3% were men, and mean the body mass index was 32.5 ± 6.3 kg/m(2). The median (interquartile range) baseline serum calcitonin values were 3.9 (1.0 to >7.6) ng/l in men and 1.0 (1.0 to >1) ng/l in women. Serum calcitonin was >10 ng/l in 14.6% of men and in 0.96% of women. In sex-specific multivariable linear analysis of covariance models, a reduced glomerular filtration rate (GFR) was associated with higher serum calcitonin concentrations that were statistically significant. A 20 ml/min/1.73 m(2) decrease in estimated GFR (eGFR) was associated with a 14% increase in serum calcitonin in women and an 11% increase in men.

Conclusions: In the LEADER population, the prevalence of elevated serum calcitonin concentrations at baseline was high, and there was an inverse association between eGFR and serum calcitonin concentrations.

Keywords: c-cell disease; calcitonin; diabetes; incretins.

© 2015 The Authors. Diabetes, Obesity and Metabolism published by JohnWiley & Sons Ltd.

Figures

Figure 1
Figure 1
Distribution of calcitonin measurements by sex. The lower limit of quantification (LLQ) for both men and women was 2.0 ng/l. The upper limit of normal was 5.0 ng/l for women and 8.4 ng/l for men.
Figure 2
Figure 2
Forest plots showing the results of multivariate log-linear analysis of calcitonin concentrations in (A) men and (B) women. For each explanatory variable, the relative effect (1 is the neutral value) is depicted together with the corresponding 95% confidence interval. The right panel cites the numbers together with the p value derived from the test of ‘no difference’. HbA1c, glycated haemoglobin; eGFR, estimated glomerular filtration rate; CVD, cardiovascular disease.

References

    1. Garber A, Henry R, Ratner R. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet. 2009;373:473–481. et al.
    1. Buse JB, Rosenstock J, Sesti G. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) Lancet. 2009;374:39–47. et al.
    1. Bjerre Knudsen L, Madsen LW, Andersen S. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473–1486. et al.
    1. Madsen LW, Knauf JA, Gotfredsen C. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012;153:1538–1547. et al.
    1. Hegedus L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011;96:853–860.
    1. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab. 2009;5:35–44.
    1. d'Herbomez M, Caron P, Bauters C. Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol. 2007;157:749–755. et al.
    1. Costante G, Meringolo D, Durante C. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92:450–455. et al.
    1. Hasselgren M, Hegedus L, Godballe C, Bonnema SJ. Benefit of measuring basal serum calcitonin to detect medullary thyroid carcinoma in a Danish population with a high prevalence of thyroid nodules. Head Neck. 2010;32:612–618.
    1. Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med. 2004;351:1764–1771.
    1. Cooper DS, Doherty GM, Haugen BR. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214. et al.
    1. Daniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid. 2011;21:1199–1207.
    1. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract. 2010;16(Suppl. 1):1–43.
    1. Paschke R, Hegedus L, Alexander E, Valcavi R, Papini E, Gharib H. Thyroid nodule guidelines: agreement, disagreement and need for future research. Nat Rev Endocrinol. 2011;7:354–361.
    1. Marso SP, Poulter NR, Nissen SE. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J. 2013;166:823–830, e825. et al.
    1. Guyetant S, Rousselet MC, Durigon M. Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. J Clin Endocrinol Metab. 1997;82:42–47. et al.
    1. Lissak B, Baudin E, Cohen R. Pentagastrin testing in patients with renal insufficiency: normal responsivity of mature calcitonin. Thyroid. 1998;8:265–268. et al.
    1. Kanbay M, Wolf M, Selcoki Y. Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease. Int Urol Nephrol. 2012;44:1169–1175. et al.
    1. Niccoli P, Brunet P, Roubicek C. Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis. Eur J Endocrinol. 1995;132:75–81. et al.
    1. Akan B, Bohmig G, Sunder-Plassmann G, Borchhardt KA. Prevalence of hypercalcitoninemia in patients on maintenance dialysis referred to kidney transplantation. Clin Nephrol. 2009;71:538–542.
    1. Healton CG, Vallone D, McCausland KL, Xiao H, Green MP. Smoking, obesity, and their co-occurrence in the United States: cross sectional analysis. BMJ. 2006;333:25–26.
    1. Erdogan MF, Gursoy A, Kulaksizoglu M. Long-term effects of elevated gastrin levels on calcitonin secretion. J Endocrinol Invest. 2006;29:771–775.
    1. Zayed AA, Alzubaidi M, Atallah S, Momani MS, Al-Delaimy WK. Should Food Intake and Circadian Rhythm be Considered When Measuring Serum Calcitonin Level. Endocr Pract. 2013;19:620–626.
    1. Giovanella L, Suriano S. Spurious hypercalcitoninemia and heterophilic antibodies in patients with thyroid nodules. Head Neck. 2011;33:95–97.
    1. Rosario PW, Calsolari MR. Influence of chronic autoimmune thyroiditis and papillary thyroid cancer on serum calcitonin levels. Thyroid. 2013;23:671–674.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel